Description

Tecentriq (Atezolizumab) is a monoclonal antibody medication used to treat various types of cancer, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), melanoma, and hepatocellular carcinoma. It works as a programmed cell death ligand 1 (PD-L1) blocking antibody. By blocking the interaction between PD-L1 and its receptors, Tecentriq allows immune cells to recognize and target cancer cells more effectively. It is supplied as an injectable solution.

Directions

Tecentriq (Atezolizumab) is administered intravenously (IV). It is typically given in a clinic or hospital setting by a trained medical professional. The standard dosage is 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks. However, the dosage may vary depending on the cancer being treated. In addition, Tecentriq may be used in combination with other cancer treatments, such as bevacizumab, depending on the type and stage of cancer being treated. Always follow the directions provided by your healthcare team.

Ingredients

The active ingredient in Tecentriq is Atezolizumab.

Contraindications

There are no known contraindications for Tecentriq. However, it may be advised to avoid taking or using Tecentriq if you have a known allergy to Atezolizumab or any of its components.

Cautions

• Before starting Tecentriq, discuss the following with a healthcare provider:
• Medical conditions, including immune system problems, a history of an organ transplant, or nervous system conditions.
• Any medications you currently take.
• Whether you are pregnant or breastfeeding.
• Tecentriq might not be suitable for everyone. Individuals with a history of severe immune reactions or allergies to similar medications should inform their doctor before starting treatment.
• As an immune checkpoint inhibitor, Tecentriq can cause an overactive immune system, potentially leading to inflammatory reactions and organ damage. Inform your doctor immediately if you notice symptoms like fever, rash, joint pain, or unusual tiredness.
• Some people might experience infusion-related reactions, including fever, chills, shortness of breath, or chest pain during or after the administration of Tecentriq. Notify your healthcare provider immediately if you develop any of these symptoms.
• Let your doctor know if you’re experiencing symptoms like cough, abdominal pain, skin rash, or any other new changes that concern you. Your doctor will do some tests before you start Tecentriq and will keep checking your health during treatment.
• If you have had or are going to have a bone marrow transplant that uses stem cells from a donor (allogeneic HSCT), using Tecentriq could lead to severe complications, some of which could be life-threatening.

Side Effects

Tecentriq (Atezolizumab) may cause side effects in some people. Common side effects include cough, decreased appetite, fatigue, nausea, and shortness of breath. In addition, some people may experience body aches or pain, dizziness, fever, and frequent urge to urinate.

Tecentriq can also cause more serious side effects, which require immediate medical attention. These include lung problems, intestinal problems, liver problems, hormone gland problems, kidney problems, skin problems, and problems in other organs. There is also a risk of infusion reactions that can sometimes be severe or life-threatening. If you experience any serious side effects, seek medical advice as soon as possible.

References

1. Tecentriq (Atezolizumab) Product Monograph. San Francisco, CA: Genentech, Inc; 2023.
2. Tecentriq (Atezolizumab) Drug Label Information. South San Francisco, CA: Genentech, Inc.; 2023.

About Dr. Gerardo Sison (Page Author)

Dr. Sison graduated with honors from the University of Florida. He began his career in pharmacy counseling patients in a community setting and later served in hospitals and clinics. He has also worked in medication therapy management services. Read More....

Product Code : 14399